Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Everolimus in Advanced Non-Clear Cell Renal Cell Carcinoma
NCT05124431Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT05124431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124431.